In The News
‘Considerable disquiet’: Pelvic mesh group members can challenge $405M settlements
Judge rejects sacked Super Retail Group execs’ settlement claims
$56M settlement approved in Monash IVF class action
Kids clothing retailer hit with $5M penalty for worker exploitation
Third person sentenced over $180M Courtenay House Ponzi scheme
Lawyerly holiday publishing schedule
Johnson & Johnson hit with class action over cold and flu medications
ASIC, Noumi win appeal in privilege fight over PwC report
‘In all circumstances unconscionable’: ASIC wins case against forex broker
Limitations defences not relevant to new claims in Victoria class actions, court told
Please login to bookmarkClose

The ACCC will face a test of its ability to win misuse of market power cases when a long-awaited judgment is handed down this week in the regulator’s appeal of a ruling dismissing its case alleging Pfizer misused its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au